10/586026 ;AP20Rec'dPCT/PTO 13 JUL 2006

Attorney Docket No.: 10515.204-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu et al.

Confirmation No: TBA

Serial No.: TBA

Group Art Unit: TBA

Filed: July 13, 2006

Examiner: TBA

For: Fungal Cell Wall Degrading Enzyme

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: July 13, 2006

Jason J. Garbell, Reg. No. 44,116 Novezymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

New York, NY 10110 (212)840-0097

AP20 REC'0 PCT/PTO 13 JUL 2008 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO				Сотр	Complete if Known		
				Application Number	FITBA 1505026		
	INFORMAT	TION DISCLOS	URE	Filing Date	July 13, 2006		
(use as many sheets as necessary)			ANT	First Named Inventor	Wu et al.		
			nry)	Art Unit	TBA		
			- ,	Examiner Name	TBA		
Sheet	1	of	2	Attorney Docket Number	10515.204-US		

		U.	S PATENT DOCU	MENTS	
Examiner Initials	Cite No. 1	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant - Figures Appear
	_				
<u> </u>					
· · ·					
	·		<u> </u>		
					
1.504					
			· · · ·		

		FOREIGN P	PATENT DOCU	MENTS		
Examiner Initials	Cite No. 1	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		EP 0425 016 A2	05-02-1991	he Procter & Gamble Co.		
		GB 2 331 750	06-02-1999	Bio-Oriented Technology		
		WO 91/06009	05-02-1991	Amgen		
		EP 1 068 871 A1	01-17-2001	Perraudin		
	<u> </u>					
						<u> </u>
						_
	<u> </u>					
	<u> </u>					

Examiner	Date			
Signature	Considere	ed		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

'AP20 Rec'd PCT/PTO 13 JUL 2006
PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Сотр	Complete if Known		
				Application Number	JBA 1506001		
	INFORMAT	TION DISCLOS	URE	Filing Date	July 13, 20060 0 0 C 0		
	STATEMENT BY APPLICANT			First Named Inventor	Wu et al.		
(use as many sheets as necessary)				Art Unit	TBA		
			••	Examiner Name	TBA		
Sheet	2	of	2	Attorney Docket Number	10515.204-US		

	- ₁	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner's Initials	Cite No. ¹	of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
		Bernard Henrissat, Biochem Journal, Vol. 280, pages 309-316 (1991)					
		Felch et al, The Journal of Biological Chemistry, Vol. 250, Part 10, pages 3713-3720 (1974)					
		Seo et al, Journal of BioScience and Bioengineering, Vol. 95, No. 3, pages 313-316 (2003)					
		Felch et al, Sequence					
		Chen et al, Water Research, Vol. 34, No. 17, pages 4229-4233 (2000)					
		Parkar et al, Journal Ind. Microbial Biotehnology, Vol. 30, pages 553-560 (2003)					
		EMBL-EBI, XP-002328312					
		Cazy-Carbohydrate-Active Enzymes XP-002327845					

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.